Ischemic Cardiomyopathy

Ischemic Cardiomyopathy Publisher

Mehrani M¹ ; Abbasi SH¹ ; Amin A² ; Kassaian SE¹ ; Mahmoudi M³

Show Affiliations

1. Tehran Heart Center, Tehran University of Medical Sciences, Tehran, Iran
2. Rajaie Cardiovascular, Medical and Research Center, Iran University of Medical Science, Tehran, Iran
3. Precision Health Program, Michigan State University, East Lansing, 48824, MI, United States

Source: Nanomedicine for Ischemic Cardiomyopathy: Progress# Opportunities# and Challenges Published:2020

Abstract

In this section, we will overview a summary of the mechanisms involved in the occurrence and progress of ischemic cardiomyopathy including pathophysiology of the heart failure and the associated roles of stunned and hibernating myocardium. We also briefly discuss how reperfusion process can cause injuries to the myocardium. Ultimately, we will summarize the stages in the development of heart failure and the conventional diagnostic approaches to identify each stage. © 2020 Elsevier Inc. All rights reserved.

2. Superparamagnetic Iron Oxide Nanoparticles for in Vivo Molecular and Cellular Imaging, Contrast Media and Molecular Imaging (2015)

3. Novel Mri Contrast Agent From Magnetotactic Bacteria Enables in Vivo Tracking of Ipsc-Derived Cardiomyocytes, Scientific Reports (2016)

4. Tumor-Associated Macrophages, Nanomedicine and Imaging: The Axis of Success in the Future of Cancer Immunotherapy, Immunotherapy (2017)

5. On-Chip Synthesis of Fine-Tuned Bone-Seeking Hybrid Nanoparticles, Nanomedicine (2015)

Experts (# of related papers)

View all Related Experts

Fatemeh Atyabi (1)

Mohamad Raoufi (1)

Style	Citing Format
MLA	Mehrani M, et al.. "Ischemic Cardiomyopathy." Nanomedicine for Ischemic Cardiomyopathy: Progress# Opportunities# and Challenges, vol. , no. , 2020, pp. 1-8.
APA	Mehrani M, Abbasi SH, Amin A, Kassaian SE, Mahmoudi M (2020). Ischemic Cardiomyopathy. Nanomedicine for Ischemic Cardiomyopathy: Progress# Opportunities# and Challenges, (), 1-8.
Chicago	Mehrani M, Abbasi SH, Amin A, Kassaian SE, Mahmoudi M. "Ischemic Cardiomyopathy." Nanomedicine for Ischemic Cardiomyopathy: Progress# Opportunities# and Challenges , no. (2020): 1-8.
Harvard	Mehrani M et al. (2020) 'Ischemic Cardiomyopathy', Nanomedicine for Ischemic Cardiomyopathy: Progress# Opportunities# and Challenges, (), pp. 1-8.
Vancouver	Mehrani M, Abbasi SH, Amin A, Kassaian SE, Mahmoudi M. Ischemic Cardiomyopathy. Nanomedicine for Ischemic Cardiomyopathy: Progress# Opportunities# and Challenges. 2020;():1-8.
BibTex	@article{ author = {Mehrani M and Abbasi SH and Amin A and Kassaian SE and Mahmoudi M}, title = {Ischemic Cardiomyopathy}, journal = {Nanomedicine for Ischemic Cardiomyopathy: Progress# Opportunities# and Challenges}, volume = {}, number = {}, pages = {1-8}, year = {2020} }
RIS	TY - JOUR AU - Mehrani M AU - Abbasi SH AU - Amin A AU - Kassaian SE AU - Mahmoudi M TI - Ischemic Cardiomyopathy JO - Nanomedicine for Ischemic Cardiomyopathy: Progress# Opportunities# and Challenges VL - IS - SP - 1 EP - 8 PY - 2020 ER -

Science Communicator Platform

Authors

Authors Affiliations

Abstract